1) Caldicott DGE, Chow FY, Burns BJ, et al:Fatalities associated with the use of γ-hydroxybutyrate and its analogues in Australasia. MJA 181:310-313, 2004
2) Dyer JE, Roth B, Hyma BA:Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 37:147-153, 2001
3) 厚生労働省医薬食品局:医薬発第1174号通知「麻薬及び向精神薬取締法施行令及び麻薬,向精神薬及び麻薬向精神薬原料を指定する政令の一部を改正する政令の施行について」.平成13年10月26日
4) 松本俊彦:薬物依存症.油井邦夫,相良洋子,加茂登志子 編.実践 女性精神医学-ライフサイクル,ホルモン,性差.創造出版,pp218-231,2005
5) McDonough M, Kennedy N, Glasper A, et al:Clinical features and management of gamma-hydroxybutyrate(GHB)withdrawal:A review. Drug Alcohol Dep 75:3-9, 2004
6) Nicholson KL, Balster RL:GHB:A new and novel drug of abuse. Drug Alcohol Dep 63:1-22, 2001
7) Palmer RB:γ-Butyrolactone and 1,4-Butanediol. Toxicol Rev 23:21-31, 2004
8) Schneir AB, Ly BT, Clark RF:A case of withdrawal from the GHB precursors Gamma-butyrolactone and 1,4-Butanediol. J Emerg Med 21:31-33, 2001
9) Shannon M, Quang LS:Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol:A case report and review of the literature. Pediatr Emerg Care 16:435-440, 2000
10) Sivilotti MLA, Burns MJ, Aaron CK, et al:Pentobarbital for severe Gamma-butyrolactone withdrawal. Ann Emerg Med 38:660-665, 2001
11) Zvosec DL, Smith SW, McCutcheon JR, et al:Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 344:87-94, 2001